ADMA Biologics, Inc. (ADMA) Stock

Understand ADMA Biologics, Inc.: how it makes money

ADMA Biologics develops, manufactures, and markets specialty plasma-derived biologics, including IVIG therapies, and makes money by selling products such as BIVIGAM and ASCENIV (and Nabi-HB) for immune deficiencies and infectious disease indications.

Profit is structurally tied to plasma collection scale and reliability, because ADMA’s specialty plasma-derived IVIG products depend on having enough collected plasma, licensed facilities, and distribution through inventories that can support product demand.

Business quality (Strong): The company’s operating drivers appear centered on plasma collection capacity and the operational throughput that supports sales of its IVIG products, with expansion under way (centers in construction) and clinical outcomes reported (real-world improvement). Key risks relate to operational dependency on plasma supply and inventory and working-capital dynamics.

Valuation: At 12× earnings, ADMA trades 28% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

• Plasma collection footprint is active: ADMA reports 10 Operational Plasma Collection Centers Collecting Plasma and 10 Food and Drug Administration Licensed Plasma Collection Facilities.
• Capacity expansion is underway: ADMA reports 3 Plasma Collection Centers In Construction, alongside Annual Plasma Collection Capacity of 600000.
• Real-world clinical improvement is reported: ADMA reports Patients Showing Clinical Improvement in Real-World Analysis of 71 percent.

Bear case

• Operational dependency on plasma collection: The model depends on collecting sufficient plasma through an operational network, and the company also reports Plasma Collection Centers In Construction of 3, which highlights that additional capacity requires ongoing execution.
• Working capital and collections timing can pressure cash flow: ADMA reports Days Sales Outstanding of 107 count, indicating collections timing is a factor to watch.
• Inventory coverage dynamics matter: ADMA reports Average Distributor Inventory Days of Coverage Above Safety Stock for Asceniv of 84 count and for BIVIGAM of 87 count, which can signal that inventory management and distributor stocking levels are important.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Tarsus Pharmaceuticals, Inc. (TARS)
• Beam Therapeutics Inc. (BEAM)
• Kodiak Sciences Inc. (KOD)
• BioCryst Pharmaceuticals, Inc. (BCRX)
• Hemab Therapeutics Holdings, Inc. (COAG)
• Vericel Corporation (VCEL)
• Recursion Pharmaceuticals, Inc. (RXRX)
• Taysha Gene Therapies, Inc. (TSHA)